| 2.92 0 (0%) | 03-19 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.64  |
1-year : | 4.2 |
| Resists | First : | 3.11 |
Second : | 3.59 |
| Pivot price | 3.22 |
|||
| Supports | First : | 2.33 |
Second : | 1.94 |
| MAs | MA(5) : | 3.1 |
MA(20) : | 3.09 |
| MA(100) : | 2.28 |
MA(250) : | 1.7 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 26.5 |
D(3) : | 46.7 |
| RSI | RSI(14): 48.3 | |||
| 52-week | High : | 3.59 | Low : | 0.85 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ABOS ] has closed below the lower bollinger band by 2.8%. Bollinger Bands are 18.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.04 - 3.06 | 3.06 - 3.07 |
| Low: | 2.76 - 2.78 | 2.78 - 2.8 |
| Close: | 2.89 - 2.92 | 2.92 - 2.95 |
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
Thu, 19 Mar 2026
Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2025 Financial Results on March 26, 2026 - The Manila Times
Thu, 19 Mar 2026
Alzheimer's drug developer Acumen sets March 26 results webcast - Stock Titan
Wed, 18 Mar 2026
RA Capital entities boost Acumen (NASDAQ: ABOS) stake with 6.1M-share grant - Stock Titan
Wed, 18 Mar 2026
ABOS: Phase II Alzheimer's trial for sabirnetug targets late 2026 data, with EBD clinical entry by 2027 - TradingView
Tue, 17 Mar 2026
Acumen Pharmaceuticals (NASDAQ:ABOS) Price Target Raised to $8.00 - MarketBeat
Tue, 17 Mar 2026
Acumen Raises Capital to Advance Enhanced Brain Delivery - The Globe and Mail
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 61 (M) |
| Shares Float | 35 (M) |
| Held by Insiders | 7.4 (%) |
| Held by Institutions | 64.6 (%) |
| Shares Short | 947 (K) |
| Shares Short P.Month | 600 (K) |
| EPS | -2.22 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.53 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -42.3 % |
| Return on Equity (ttm) | -86 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -1.97 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.29 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -124 (M) |
| Levered Free Cash Flow | -79 (M) |
| PE Ratio | -1.33 |
| PEG Ratio | 0 |
| Price to Book value | 1.89 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.44 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|